Regarding the identification of predictive factors for neoadjuvant treatments, we evaluated immunohistochemical PD-L1 expression since it is a critical marker to guide patient selection for immunotherapy in advanced NSCLC. This evidence concerns the gene CD274 and non-small cell lung carcinoma.